文献速递药物不良反应与药物警戒抗栓抗凝管理

丹麦抗凝治疗相关颅内出血:自发不良反应报告与真实世界数据的比较

Intracranial Hemorrhage Following Anticoagulant Treatment in Denmark: Spontaneous Adverse Drug Reaction Reports Versus Real-World Data.
PubMed 文献 · Drug Saf · 2022-03-19

该研究基于丹麦全国登记数据(2014—2018年),估算华法林及三种直接口服抗凝药相关颅内出血作为不良反应的上报不足程度。结果显示,华法林相关颅内出血事件中97.0%未上报,DOACs的上报不足率在88.8%至90.8%之间,提示存在严重且因药而异的上报不足。

要点

  • 华法林相关ICH事件中97.0%未作为不良反应上报。
  • DOACs相关ICH上报不足率介于88.8%至90.8%。
  • 自发报告数据不宜直接用于比较抗凝药ICH风险。

核心结论

  • 四种研究药物相关颅内出血作为不良反应的上报存在严重且因药而异的上报不足。

研究设计与样本

  • 观察性研究,覆盖2014—2018年5年期间,利用丹麦健康数据管理局全国登记数据估算各研究药物的使用者数、暴露人年及相关ICH事件。
  • 不良反应ICH报告数据提取自丹麦药品管理局的交互式不良反应概览。

主要发现

  • 2014至2018年间,华法林相关ICH事件中97.0%未作为不良反应上报。
  • DOACs的上报不足率范围为88.8%至90.8%。

临床怎么用

  • 解读抗凝药自发不良反应报告时需考虑严重上报不足,不宜直接据此比较不同抗凝药的ICH风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In Denmark, physicians are legally obliged to report serious adverse drug reactions (ADRs), such as intracranial hemorrhage (ICH) following anticoagulant (AC) treatment, to the Danish Medicines Agency. We were therefore puzzled to discover a high number of reports concerning ICHs following treatment with the direct oral anticoagulants (DOACs) dabigatran, rivaroxaban, and apixaban compared with warfarin. This was surprising, as all DOACs have been found to be associated with a lower risk of ICH compared with warfarin in phase III randomized controlled trials. OBJECTIVES: The primary aim of the study was to estimate the level of underreporting of ICH as an ADR following treatment with warfarin, dabigatran, rivaroxaban, and apixaban. METHODS: This observational study covered a 5-year period (2014-2018). Using nationwide registries held by the Danish Health Data Authority, the number of users, exposure time in person-years, and related ICH events for each of the study drugs were estimated. Data on ADR-ICH reports were extracted from the interactive ADR overviews held by the Danish Medicines Agency. RESULTS: From 2014 to 2018, 97.0% of the identified warfarin-related ICH events were not reported as ADRs. For the DOACs, the level of underreporting ranged from 88.8 to 90.8%. CONCLUSION: We found a heavy and differentiated level of underreporting of ICH as an ADR following treatment with the four study drugs.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. von Osmanski BI, Schelde AB, Jimenez-Solem E, et al. Intracranial Hemorrhage Following Anticoagulant Treatment in Denmark: Spontaneous Adverse Drug Reaction Reports Versus Real-World Data. Drug Saf. 2022. PMID: 35305263. doi:10.1007/s40264-022-01147-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。